Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

202
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
202
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

174
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
174
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

163
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
163
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

160
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
160
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Depressants01:28

Depressants

99
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal subfields volumes and affective symptoms of patients with mesial temporal lobe epilepsy.

Epilepsy & behavior : E&B·2025
Same author

Prediction of COVID-19 mortality using machine learning strategies and a large-scale panel of plasma inflammatory proteins: A cohort study.

Medicina intensiva·2025
Same author

Association of systemic inflammation and long-term dysfunction in COVID-19 patients: A prospective cohort.

Psychoneuroendocrinology·2025
Same author

Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients.

Critical care science·2024
Same author

The epileptic heart: Cardiac comorbidities and complications of epilepsy. Atrial and ventricular structure and function by echocardiography in individuals with epilepsy - From clinical implications to individualized assessment.

Epilepsy & behavior reports·2024
Same author

Detection of seizures with ictal tachycardia, using heart rate variability and patient adaptive logistic regression machine learning methods: A hospital-based validation study.

Epileptic disorders : international epilepsy journal with videotape·2024

Related Experiment Video

Updated: Jun 7, 2025

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

868

Cannabinoid for alcohol use disorder.

Júlia Dalfovo Marquez1, Talissa Dezanetti1, Roger Walz2

  • 1Programa de Pós-Graduação em Neurociências, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Brazil.

International Review of Neurobiology
|November 10, 2024
PubMed
Summary
This summary is machine-generated.

Cannabis and alcohol combined may pose risks, but cannabinoid compounds show potential for treating alcohol use disorder (AUD). Research explores both the benefits and dangers of this combination for AUD treatment.

Keywords:
AbstinenceAddictionAlcoholAlcohol use disorderCannabinoidCannabisCravingMarijuanaSubstitution therapy

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

7.9K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K

Related Experiment Videos

Last Updated: Jun 7, 2025

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

868
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

7.9K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Medicine

Background:

  • The endocannabinoid system influences brain reward pathways and drug abuse.
  • Cannabinoid receptors (CB1 and CB2) may modulate addiction properties.
  • Cannabis and alcohol are frequently co-used, with potential implications for alcohol use disorder (AUD).

Purpose of the Study:

  • To review evidence on the benefits and risks of combining alcohol and cannabis.
  • To explore the therapeutic potential of cannabinoid compounds for AUD.
  • To address the growing availability of cannabis due to legalization.

Main Methods:

  • Literature review of existing studies on cannabis, alcohol, and the endocannabinoid system.
  • Analysis of research on the co-use of alcohol and cannabis.
  • Examination of preclinical and clinical data regarding cannabinoid therapies for AUD.

Main Results:

  • Some evidence suggests cannabis may aid AUD treatment, acting as a substitute medication.
  • Concomitant use of alcohol and cannabis can increase the risk of adverse outcomes.
  • Cannabinoid compounds show promise, but risks associated with combined use require careful consideration.

Conclusions:

  • The combination of alcohol and cannabis presents both potential therapeutic avenues and significant risks for AUD.
  • Further research is needed to clarify the precise role of cannabinoids in AUD treatment and to mitigate risks of co-use.
  • Cannabinoid-based therapies warrant investigation for AUD, balancing potential benefits against known risks.